Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant

Authors

S. Maheshwari, Inova Children's Hospital, Falls Church, VA
A. Kassim, Vanderbilt University
R. F. Yeh, Seattle Cancer Care Alliance, Seattle, WA
J. Domm, Vanderbilt University
C. Calder, Vanderbilt University
M. Evans, Vanderbilt University
B. Manes, Vanderbilt University
V. Brown, Vanderbilt University
R. Ho, Vanderbilt University
H. Frangoul, Vanderbilt University
Elizabeth Yang, George Washington University

Document Type

Journal Article

Publication Date

3-2014

Journal

Bone Marrow Transplantation

Volume

Volume 49, Issue 3

Inclusive Pages

366-369

Keywords

Anemia, Sickle Cell--drug therapy; Anemia, Sickle Cell--therapy; Busulfan--therapeutic use; HLA Antigens--chemistry

APA Citation

Maheshwari, S., Kassim, A., Yeh, R.F., Domm, J., Calder, C. et al. (2014). Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplantation, 49(3), 366-369.

Peer Reviewed

1